Age-related patterns of organ damage impact on health-related quality of life in SLE Authors: Wan-Yun Hsu, Li-Yun Tsai, I-Chieh Chen, Jun-Peng Chen, Kai-Ting Chen, Chung-Mao Kao, Yen-Ju Chen, Kuo-Tung Tang, Wei-Ting Hung, Wen-Nan Huang, Yi-Ming Chen Published: 2025 ABSTRACT AbstractObjectiveTo characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in patients with SLE and to identify specific damage patterns affecting physical and mental health outcomes across different age groups.MethodsIn this cross-sectional study, 1149 patients with SLE from the Asia Pacific Lupus Collaboration cohort were stratified by age. HRQoL was assessed using the Short Form-36 questionnaire. Clinical characteristics and organ damage (Systemic Lupus International Collaborating Clinics (SLICC) Damage Index) were evaluated. Multiple linear regression analyses identified factors associated with the Physical (PCS) and Mental Component Summary (MCS) scores.ResultsSignificant age-related differences were observed in physical HRQoL, with the age group ≥50 years showing lower PCS scores (median 52.6) than the age groups <20 years (56.9) and 20–50 years (57.5) (p<0.001). In multivariable models, higher SLICC Damage Index (β=−1.39), lower educational attainment (β=−7.02) and prednisolone use (β=−1.85) were independently associated with lower PCS scores. MCS scores were positively associated with male gender (β=4.40) and secondary education (β=2.46), but negatively impacted by higher damage index (β=−0.90) and cyclophosphamide use (β=−5.44). Specific damage patterns, such as avascular necrosis, particularly impaired bodily pain and physical functioning domains.ConclusionAge-related differences in SLE predominantly affect physical rather than mental aspects of HRQoL. Cumulative organ damage remains a central modifiable factor associated with poorer outcomes across all ages. These findings emphasise the importance of age-specific management strategies and early damage prevention to optimise long-term HRQoL in patients with SLE.Keywords: Systemic Lupus Erythematosus; Health-Related Quality Of Life; Lupus Erythematosus, Systemic; Quality of LIfe WHAT IS ALREADY KNOWN ON THIS TOPIC SLE impairs quality of life, but age-stratified analyses examining differential impacts across life stages remain limited. SLE impairs quality of life, but age-stratified analyses examining differential impacts across life stages remain limited. WHAT THIS STUDY ADDS In 1149 SLE patients, age-related deterioration predominantly affects physical functioning, with higher damage scores independently predicting worse outcomes. In 1149 SLE patients, age-related deterioration predominantly affects physical functioning, with higher damage scores independently predicting worse outcomes. Higher Systemic Lupus International Collaborating Clinics Damage Index scores independently predict worse physical (β=−1.39) and mental (β=−0.90) quality of life outcomes across all age groups. Higher Systemic Lupus International Collaborating Clinics Damage Index scores independently predict worse physical (β=−1.39) and mental (β=−0.90) quality of life outcomes across all age groups. Specific damage manifestations, particularly avascular necrosis, disproportionately impact bodily pain and physical functioning, identifying priority areas for intervention. Specific damage manifestations, particularly avascular necrosis, disproportionately impact bodily pain and physical functioning, identifying priority areas for intervention. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY Findings support age-tailored care prioritising physical rehabilitation for older patients and aggressive early treatment for damage prevention. Findings support age-tailored care prioritising physical rehabilitation for older patients and aggressive early treatment for damage prevention. Introduction SLE is a chronic autoimmune disease with heterogeneous presentation across the lifespan.1 Health-related quality of life (HRQoL) has gained recognition as a critical outcome measure in SLE management, reflecting the broader impact of the disease beyond traditional clinical parameters.2 3 Despite improved survival rates, SLE patients experience significantly reduced HRQoL compared with the general population.4 Age-related variations in SLE presentation are well-documented, with younger patients often experiencing more acute manifestations including renal and neurological involvement, while older-onset SLE typically presents with more serositis, pulmonary involvement and damage accrual from comorbidities.5 6 These differences in disease expression may translate to varied impacts on physical and mental health (MH) dimensions across age groups. Previous research has demonstrated important age-related differences in HRQoL among SLE patients. The Georgians Organized Against Lupus study found that older age was associated with lower physical functioning (PF) but not MH scores, highlighting the need for age-stratified analyses when examining quality of life outcomes in SLE populations.7 These findings support the rationale for our current investigation into age-related patterns of organ damage and their differential impact on physical and MH outcomes. Several factors potentially influence HRQoL in SLE patients, including disease activity, accumulated organ damage, medication side effects and sociodemographic characteristics.8 9 Traditional clinical parameters used in SLE management, such as anti-dsDNA antibodies, complement levels (C3/C4) and disease activity scores including SLE Disease Activity Index (SLEDAI), predominantly focus on the immunological and inflammatory aspects of the disease. However, these conventional measures may not adequately capture the patient’s subjective health experience and functional capacity, which are fundamental determinants of HRQoL. The European Alliance of Associations for Rheumatology (EULAR) recommendations for SLE management emphasise the importance of incorporating HRQoL assessment into routine clinical practice.9 Despite this recognition, comprehensive studies examining age-related differences in HRQoL patterns among SLE patients with varying degrees of organ damage remain limited, highlighting the need for further investigation into these complex relationships. While previous studies have examined HRQoL in SLE patients, most have been limited by smaller sample sizes, lack of age-stratified analyses or limited examination of the differential impact of specific organ damage manifestations on quality of life domain. This study addresses these gaps by providing a comprehensive analysis of age-related differences in HRQoL with particular focus on how specific types of organ damage impact different dimensions of well-being in a large cohort of SLE patients. This study aimed to investigate age-specific differences in HRQoL among SLE patients, with particular focus on how organ damage affects physical and MH outcomes. We sought to identify clinical, laboratory and demographic determinants of HRQoL while examining the distinct patterns by which specific organ damage manifestations impact different quality of life domains across age groups. Methods Study design and participants This cross-sectional study included 1149 patients from the Asia Pacific Lupus Collaboration (APLC) cohort as previously described. The APLC is a multinational inception cohort that enrols newly diagnosed SLE patients from multiple centres across the Asia-Pacific region.8 This inception cohort design allows for prospective follow-up from early disease stages, facilitating comprehensive assessment of disease progression and long-term outcomes. SLE was defined by the American College of Rheumatology (ACR) classification criteria for SLE or the Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria.9 10 Participants were recruited from the lupus clinic of a tertiary medical centre between January 2022 and December 2024. For patients diagnosed prior to 2019, classification was based on the 1997 ACR criteria, which were the standard at the time. For patients diagnosed from 2019 onwards, the SLICC criteria were applied. The study protocol was approved by the institutional ethics committee (IRB No. CE17061B), and all participants provided written informed consent. Patients were categorised into three age groups: <20 years (n=180), 20–50 years (n=839) and ≥50 years (n=130), representing distinct life stages: adolescence/early adulthood, middle adulthood and later adulthood. Measurements Clinical assessment Demographic data, disease duration, smoking status and educational level were collected via structured interviews. Disease activity was assessed using the SLEDAI,11 and cumulative organ damage was evaluated using the SLICC/ACR Damage Index (SLICC/ACR DI).12 13 Clinical manifestations were documented according to the ACR criteria. Current medications, including corticosteroids and immunosuppressants, were recorded. Laboratory parameters Laboratory parameters included renal function indicators (serum creatinine, estimated glomerular filtration rate (eGFR), urine protein/creatinine ratio), haematological parameters (haemoglobin, white blood cell count, platelet count, lymphocyte count) and immunological markers (anti-double stranded DNA (dsDNA) antibodies, complement C3 and C4 levels). HRQoL assessment HRQoL was assessed using the validated Short Form-36 (SF-36) health survey questionnaire.14 The SF-36 evaluates eight domains of health: PF, role limitations due to physical health, bodily pain (BP), general health (GH) perceptions, vitality (VT), social functioning (SF), role limitations due to emotional problems and MH. These domains are further summarised into Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Higher scores indicate better health status, with scores ranging from 0 to 100. All SF-36 items were scored on a 1–5 Likert scale, with higher scores indicating better health. The SF-36 questionnaire used in this study was the Traditional Chinese version validated in Taiwanese populations with demonstrated reliability (Cronbach’s alpha ranging from 0.78 to 0.93 across domains) and construct validity through known-groups comparison. Age categorisation (<20 years, 20–50 years and ≥50 years) was determined based on developmental life stages and previous literature demonstrating distinct patterns of disease expression and psychosocial adaptation across these age groups. Six specific organ damage manifestations were selected for detailed analysis based on their prevalence in our cohort: cataracts, reduced eGFR (<50%), osteoporosis, avascular necrosis, diabetes mellitus and malignancy. These manifestations represented the most frequently observed forms of damage and provided a comprehensive spectrum of organ system involvement characteristic of SLE-related damage accrual. Statistical analysis Continuous variables were presented as median and IQR and categorical variables as frequencies and percentages. The Kruskal-Wallis test was used to compare continuous variables across age groups, and the χ2 test was used for categorical variables. Multiple linear regression analyses were performed to identify factors associated with PCS and MCS scores. Variables with p<0.1 in univariate analyses were included in the multivariable models. Results were presented as regression coefficients (β) with 95% CIs. To assess the impact of specific organ damage manifestations on HRQoL domains, radar chart analyses were performed comparing SF-36 domain scores between patients with specific manifestations (cataracts, reduced GFR <50%, osteoporosis, avascular necrosis, diabetes mellitus and malignancy) and those without any damage. Statistical analyses were performed using SPSS V.22.0 (IBM, Armonk, New York, USA). A two-sided p value<0.05 was considered statistically significant. Results Patient characteristics by age group Table 1 presents the demographic and clinical characteristics of the study participants stratified by age groups. The majority of patients were female (90.4%), with a higher proportion of males in the age group ≥50 years (20.0%) compared with the age groups <20 years (10.6%) and 20–50 years (7.7%) (p<0.001). The median disease duration was significantly shorter in the age group ≥50 years (11.0 years) compared with the age groups <20 years (21.0 years) and 20–50 years (20.0 years) (p<0.001). Table 1Demographic and clinical characteristics of patients stratified by onset age groupsVariableTotal(n=1149)<20 years(n=180)20–50 years(n=839)≥50 years(n=130)P valueGender<0.001** Female1039 (90.4%)161 (89.4%)774 (92.3%)104 (80.0%) Male110 (9.6%)19 (10.6%)65 (7.7%)26 (20.0%) Diagnosis age (years)31.0 (23.0–41.0)16.0 (13.25–18)32.0 (26.0–38.0)57.0 (53.0–63.0)<0.001** Current age (years)50.0 (42.0–60.0)37.0 (32.0–44.0)51.0 (44.0–58.0)71.0 (64.8–78.0)<0.001** Disease duration (years)13.0 (6.0–17.0)17.0 (11.0–22.0)13.0 (6.0–17.0)5.0 (1.0–12.0)<0.001**Smoking72 (6.3%)7 (3.9%)54 (6.4%)11 (8.5%)0.242Education level<0.001** Primary68 (5.9%)1 (0.6%)15 (1.8%)52 (40.0%) Secondary87 (7.6%)5 (2.8%)67 (8.0%)15 (11.5%) Tertiary994 (86.5%)174 (96.7%)757 (90.2%)63 (48.5%)ACR criteria at diagnosis Renal disorder542 (47.2%)97 (53.9%)403 (48.0%)42 (32.3%)0.001** Neurological disorder84 (7.3%)18 (10.0%)57 (6.8%)9 (6.9%)0.320 Haematological disorder719 (62.6%)121 (67.2%)523 (62.3%)75 (57.7%)0.223SLEDAI score2.0 (0.0–4.0)4.0 (2.0–4.0)4.0 (2.0–4.0)2.0 (0.0–4.0)0.007**SLICC Damage Index0.0 (0.0–1.0)0.0 (0.0–1.0)0.0 (0.0–1.0)1.0 (0.0–1.0)<0.001**Renal function indicators Creatinine (mg/dL)0.8 (0.7–0.9)0.7 (0.6–0.9)0.7 (0.7–0.9)0.8 (0.7–1.0)<0.001** eGFR (mL/min/1.73 m²)92.1 (73.6–108.1)103.6 (85.1–119.5)91.9 (74.0–107.7)79.4 (63.2–94.3)<0.001** Urine protein/creatinine ratio0.02 (0.01–0.06)0.02 (0.01–0.06)0.02 (0.01–0.06)0.02 (0.01–0.05)0.651Haematological indicators Haemoglobin (g/dL)127.0 (114.0–137.0)126.0 (114.0–137.0)127.0 (114.0–137.0)128.0 (114.0–137.0)0.915 WBC (×10³/μL)5800.0(4480.0–7675.0)6060.0 (4332.5–8245.0)5760.0 (4520.0–7520.0)5795.0 (4547.5–7722.5)0.676 Platelet (×10³/μL)234.0 (189.0–285.0)251.5 (201.0–300.0)235.0 (189.5–285.5)210.0 (171.5–261.0)<0.001** Lymphocyte (×10³/μL)1279.5 (879.0–1779.3)1164.5 (742.3–1784.5)1279.0 (888.0–1760.8)1447.5 (950.8–1843.0)0.063Immunological indicators anti-double stranded DNA (IU/mL)0.437 Negative346 (30.1%)47 (26.1%)258 (30.8%)41 (31.5%) Positive803 (69.9%)133 (73.9%)581 (69.2%)89 (68.5%) Complement C3 (mg/dL)<0.001** <88434 (37.8%)80 (44.4%)324 (38.7%)30 (23.1%) ≥88713 (62.2%)100 (55.6%)513 (61.3%)100 (76.9%) Complement C4 (mg/dL)0.016* <15386 (33.6%)71 (39.4%)284 (33.9%)31 (23.8%) ≥15762 (66.4%)109 (60.6%)554 (66.1%)99 (76.2%) Prednisolone use919 (80.0%)156 (86.7%)667 (79.5%)96 (73.8%)0.017* Prednisolone daily dose (mg)5 (5.0–10.0)7.5 (5.0–10.0)5.0 (5.0–10.0)5.0 (3.1–10.0)0.049* Hydroxychloroquine use1048 (91.2%)163 (90.6%)767 (91.4%)118 (90.8%)0.917 Hydroxychloroquine dose200.0 (200.0–400.0)200.0 (200.0–400.0)200.0 (200.0–400.0)200.0 (200.0–400.0)0.355Immunosuppressant use Azathioprine352 (30.6%)65 (36.1%)256 (30.5%)31 (23.8%)0.068 Mycophenolate/mycophenolic acid233 (20.3%)42 (23.3%)179 (21.3%)12 (9.2%)0.003** Ciclosporin92 (8.0%)22 (12.2%)63 (7.5%)7 (5.4%)0.054 Cyclophosphamide11 (1.0%)1 (0.6%)6 (0.7%)4 (3.1%)0.030* Rituximab15 (1.3%)1 (0.6%)13 (1.5%)1 (0.8%)0.481 Belimumab26 (2.3%)3 (1.7%)22 (2.6%)1 (0.8%)0.352 Tacrolimus19 (1.7%)7 (3.9%)12 (1.4%)0 (0.0%)0.019**p<0.05, **p<0.01.ACR, American College of Rheumatology; SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics. Demographic and clinical characteristics of patients stratified by onset age groups *p<0.05, **p<0.01. ACR, American College of Rheumatology; SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics. Educational levels differed significantly across age groups, with tertiary education being more common in the <20 years (96.7%) and 20–50 years (90.2%) groups compared with the ≥50 years group (48.5%) (p<0.001). Regarding ACR criteria at diagnosis, renal disorder was more prevalent in the age group <20 years (53.9%) compared with the age groups 20–50 years (48.0%) and ≥50 years (32.3%) (p=0.001). Laboratory parameters showed age-related differences in renal function, with higher eGFR in the <20 years group (103.6 mL/min/1.73 m²) compared with the age groups 20–50 years (91.9 mL/min/1.73 m²) and ≥50 years (79.4 mL/min/1.73 m²)(p<0.001). Among the study participants, 346 patients (30.1%) had negative results while 803 patients (69.9%) showed positive results. The distribution across subgroups was as follows: in the age group <20 years, 47 patients (26.1%) were negative and 133 patients (73.9%) were positive; in the group 20–50 years, 258 patients (30.8%) were negative and 581 patients (69.2%) were positive and in the group ≥50 years, 41 patients (31.5%) were negative and 89 patients (68.5%) were positive. The proportions of positive and negative cases remained relatively consistent across all subgroups, with positive results predominating in each group. These categorical classifications were subsequently used in multivariate analyses to evaluate their associations with clinical outcomes. Complement levels showed age-related patterns, with C3 and C4 levels being significantly higher in the ≥50 years group compared with the younger age groups (p=0.002 and p<0.001, respectively). Regarding medication use, steroid use was more common in the <20 years group (86.7%) compared with the 20–50 years (79.5%) and ≥50 years (73.8%) groups (p=0.017). Mycophenolate/mycophenolic acid use was significantly less frequent in the age group ≥50 years (9.2%) compared with the age group <20 years (23.3%) and 20–50 years (21.3%)(p=0.003). HRQoL across age groups Physical health dimensions The PCS score was significantly lower in the group ≥50 years (median 52.59) compared with the groups <20 years (56.88) and 20–50 years (57.50) (p<0.001, table 2 and online supplemental table 1). Table 2Comparison of physical health and mental health dimensions across age groupsVariableTotal(n=1149)Age <20 years(n=180)Age 20–50 years(n=839)Age ≥50 years(n=130)P valuePhysical functioning90.00 (75.00–95.00)90.00 (80.00–100.00)90.00 (75.00–100.00)80.00 (60.00–90.00)<0.001**Role limitations due to physical health75.00 (50.00–93.75)75.00 (51.56–87.50)75.00 (50.00–93.75)56.25 (25.00–81.25)<0.001**Pain22.22 (0.00–33.33)11.11 (0.00–33.33)11.11 (0.00–33.33)22.22 (0.00–33.33)0.299General health perceptions55.00 (45.00–60.00)50.00 (45.00–60.00)55.00 (45.00–60.00)55.00 (45.00–60.00)0.173Physical component summary56.88 (51.16–61.55)56.88 (52.93–61.25)57.50 (51.74–62.36)52.59 (42.67–59.07)<0.001**Role limitations due to emotional problems75.00 (50.00–100.00)75.00 (58.33–100.00)75.00 (58.33–100.00)75.00 (50.00–100.00)0.599Vitality50.00 (43.75–56.25)50.00 (43.75–56.25)50.00 (43.75–56.25)56.25 (50.00–62.50)<0.001**Mental health50.00 (45.00–55.00)50.00 (45.00–55.00)50.00 (45.00–55.00)55.00 (45.00–60.00)0.011*Social functioning37.50 (37.50–50.00)37.50 (37.50–50.00)37.50 (37.50–50.00)50.00 (25.00–50.00)0.550Mental component summary53.96 (47.55–60.63)54.38 (48.49–59.97)53.75 (47.19–60.31)54.27 (47.11–63.75)0.611Kruskal-Wallis test was used; data were presented as median (IQR).*p<0.05, **p<0.01. Comparison of physical health and mental health dimensions across age groups Kruskal-Wallis test was used; data were presented as median (IQR). *p<0.05, **p<0.01. PF scores were significantly lower in the group ≥50 years (median 80.00) compared with the groups <20 years (90.00) and 20–50 years (90.00) (p<0.001). Specifically, older patients reported more limitations in vigorous activities, moderate activities, lifting/carrying groceries, climbing several flights of stairs and bending/kneeling (all p<0.001). Role limitations due to physical health were also more pronounced in the group ≥50 years (median 56.25) compared with the groups <20 years (75.00) and 20–50 years (75.00) (p<0.001). No significant differences were observed across age groups in BP (p=0.299) or GH perceptions (p=0.173). MH dimensions The MCS score did not differ significantly between age groups (p=0.611, table 2 and online supplemental table 2). VT scores were significantly higher in the group ≥50 years (median 56.25) compared with the groups <20 years (50.00) and 20–50 years (50.00)(p<0.001). Older patients reported feeling less tired (p<0.001) and more full of life (p=0.002) compared with younger patients. MH scores were marginally higher in the group ≥50 years (median 55.00) compared with the younger age groups (both median 50.00) (p=0.011). No significant differences were observed across age groups in role limitations due to emotional problems (p=0.599) or SF (p=0.550). Factors associated with PCS In the multivariable model (table 3 and online supplemental table 3), factors negatively associated with PCS included primary education (β=−7.02, p<0.001), SLICC DI (β=−1.39, p<0.001), prednisolone use (β=−1.85, p=0.004) and age ≥50 years (β=−3.04, p=0.007). Haemoglobin level was positively associated with PCS (β=0.05, p<0.001). The age group 20–50 years was not significantly different from the age group <20 years in terms of PCS after adjusting for other variables (β=0.29, p=0.679). Table 3Linear regression analysis of factors associated with the Physical Component Summary scoreVariableMultivariable β (95% CI)P valueAge group <20 yearsReference 20–50 years0.29 (−1.10 to 1.68)0.679 ≥50 years−3.04 (−5.24 to −0.84)0.007**Educational level TertiaryReference Primary−7.02 (−9.50 to −4.53)<0.001** Secondary−1.77 (−3.68 to 0.14)0.069Disease activity and damage SLICC Damage Index−1.39 (−1.96 to −0.82)<0.001**Haematologic markers Haemoglobin (g/dL)0.05 (0.03 to 0.08)<0.001** White blood cells (/μL)−0.22 (−0.41 to −0.27)0.002**Steroid use Prednisolone (mg/day)−1.85 (−3.12 to −0.58)0.004****p<0.01.SLICC, Systemic Lupus International Collaborating Clinics. Linear regression analysis of factors associated with the Physical Component Summary score **p<0.01. SLICC, Systemic Lupus International Collaborating Clinics. Factors associated with MCS In the multivariable model (table 4 and online supplemental table 4), male gender (β=4.40, p<0.001) and secondary education (β=2.46, p=0.015) were positively associated with MCS. SLICC DI (β=−0.90, p=0.003) and cyclophosphamide use (β=−5.44, p=0.046) were negatively associated with MCS. Table 4Linear regression analysis of factors associated with the Mental Component Summary scoreVariableMultivariable β (95% CI)P valueGender FemaleReference Male4.40 (2.57 to 6.24)<0.001**Educational level TertiaryReference Primary2.21 (−0.04 to 4.46)0.054 Secondary2.46 (0.47 to 4.45)0.015*Disease activity and damage SLEDAI score−0.08 (−0.25 to 0.08)0.311 SLICC Damage Index−0.90 (−1.49 to −0.30)0.003**Haematological markers Haemoglobin (g/dL)0.02 (−0.01 to 0.05)0.177 Lymphocytes (/μL)0.70 (−0.15 to 1.56)0.109Steroid use Prednisolone (mg/day)−1.14 (−2.50 to 0.22)0.102Immunosuppressants Cyclophosphamide−5.44 (−10.78 to −0.10)0.046*Linear regression analysis.*p<0.05; **p<0.01.SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics. Linear regression analysis of factors associated with the Mental Component Summary score Linear regression analysis. *p<0.05; **p<0.01. SLEDAI, SLE Disease Activity Index; SLICC, Systemic Lupus International Collaborating Clinics. Notably, age group was not independently associated with MCS in the multivariable model, suggesting that the observed differences in MH dimensions were mediated by other factors. Impact of specific organ damage on HRQoL domains The radar plot analysis compared SF-36 domain scores between patients with specific organ damage and those without damage across eight domains: PF), role physical (RP), BP, GH, vitality (VT), SF, role emotional and MH. Among the 1149 patients analysed, 719 (62.6%) had no organ damage, while specific damage manifestations were observed as follows: cataracts in 83 patients (7.2%), osteoporosis in 129 patients (11.2%), avascular necrosis in 65 patients (5.7%), reduced GFR <50% in 46 patients (4.0%), diabetes mellitus in 49 patients (4.3%) and malignancy in 37 patients (3.2%) (figure 1). The analysis revealed distinct patterns of domain score reductions across different damage types. Patients with avascular necrosis demonstrated the largest decrements in physical domains (PF, RP and BP), while those with malignancy and reduced renal function showed score reductions across multiple domains including both physical and MH components. The analysis revealed distinct patterns of domain score reductions across different damage types. Patients with avascular necrosis demonstrated the largest decrements in physical domains (PF, RP and BP), while those with malignancy and reduced renal function showed score reductions across multiple domains including both physical and MH components. The analysis revealed distinct patterns of domain score reductions across different damage types. Patients with avascular necrosis demonstrated the largest decrements in physical domains (PF, RP and BP), while those with malignancy and reduced renal function showed score reductions across multiple domains including both physical and MH components. These prevalence data provide important context for interpreting the differential impacts of specific organ damage patterns on HRQoL outcomes and demonstrate the distribution of damage manifestations in our study population. Impact of Specific Organ Damage on health-related quality of life domains. The radar plot analysis compared SF-36 domain scores between patients with specific organ damage and those without damage across eight domains: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH). Among the 1149 patients analysed, 719 (62.6%) had no organ damage, while specific damage manifestations were observed as follows: cataracts in 83 patients (7.2%), osteoporosis in 129 patients (11.2%), avascular necrosis in 65 patients (5.7%), reduced GFR <50% in 46 patients (4.0%), diabetes mellitus in 49 patients (4.3%) and malignancy in 37 patients (3.2%). The analysis revealed distinct patterns of domain score reductions across different damage types. Patients with avascular necrosis demonstrated the largest decrements in physical domains (PF, RP, BP), while those with malignancy and reduced renal function showed score reductions across multiple domains including both physical and mental health components. eGFR, estimated glomerular filtration rate. Patients with reduced eGFR (<50%) exhibited substantial impairment across multiple domains, with particularly notable deficits in GH, PF and RP. This comprehensive impact underscores how renal dysfunction affects not only physiological capabilities but also patients’ overall perception of health status and ability to fulfil daily roles. Malignancy was associated with substantial reductions across all SF-36 domains, with the most severe effects observed in RP, GH and VT. This pattern reflects the multidimensional burden of cancer and its treatments, affecting patients’ energy levels, ability to perform routine activities and overall health perceptions. Osteoporosis exhibited a characteristic profile with marked reductions in PF, BP and RP. The significant impairment in these physical domains highlights how bone fragility and associated discomfort directly constrain mobility and daily activities. Cataracts showed moderate yet significant reductions across all domains compared with controls, with the most pronounced differences in PF, RP and GH. These findings suggest that visual impairment extends beyond direct functional limitations to affect broader aspects of health perception and daily role performance. Diabetes mellitus presented a more uniform reduction across all domains compared with controls, with GH, PF and VT being most affected. This pattern reflects the pervasive nature of this metabolic condition, impacting patients’ energy levels, physical capabilities and overall health perceptions. These distinctive patterns of domain-specific impairment across conditions provide valuable insights for clinical prioritisation and targeted interventions. The visualisation through radar plots effectively illustrates how different chronic conditions uniquely affect specific dimensions of HRQoL, suggesting that therapeutic approaches should be tailored to address the most severely affected domains for each condition. Physical domains were generally more severely affected than mental and social domains across most conditions, suggesting potential psychological adaptation or coping mechanisms that partially mitigate effects on MH domains. Discussion This comprehensive study of 1149 SLE patients demonstrates significant age-related differences in how organ damage impacts HRQoL outcomes. Our findings reveal that older SLE patients (≥50 years) experience substantially poorer PF and more severe role limitations due to physical health when organ damage is present, compared with their younger counterparts, while MH dimensions show more complex patterns across age groups. These age-specific vulnerabilities highlight that organ damage serves as an impactful determinant of HRQoL depending on patient age. The SLICC DI showed significant negative associations with both PCS and MCS across all age groups, yet the magnitude and pattern of these associations varied considerably with age. Distinct patterns of impairment were observed across different damage manifestations, with age modifying the relationship between specific organ damage types and quality of life domains. The lower physical component scores observed in older SLE patients align with previous research on ageing and HRQoL in both SLE and the general population.15 16 However, our study identifies several SLE-specific factors that contribute to these age-related differences. The shorter disease duration in the older age group suggests that older patients may experience more rapid functional decline despite later disease onset. This finding is consistent with previous research indicating that older-onset SLE is associated with higher damage accrual rates and poorer physical outcomes.17 18 The negative association between SLICC DI and both physical and mental component scores across all age groups highlights the central role of organ damage in determining HRQoL, regardless of patient age. Our finding of no significant independent association between age group and MCS aligns with several observations in the SLE literature. A previous study reported that age was not a significant predictor of MH outcomes in SLE patients, suggesting that disease-specific factors may override typical age-related MH patterns observed in the general population.7 This contrasts with studies in other chronic conditions such as rheumatoid arthritis and diabetes, where older age is often associated with better psychological adaptation and lower rates of depression and anxiety. The absence of age-related differences in MH outcomes in SLE may reflect the unique psychological burden of this multisystem autoimmune disease, where unpredictable flares, diverse organ involvement and cosmetic concerns affect patients across all age groups. Additionally, younger SLE patients may experience particular psychological challenges related to disrupted life plans, career impacts and reproductive concerns, potentially offsetting any age-related improvements in coping or resilience typically seen in other chronic diseases. This emphasises the importance of damage prevention strategies in SLE management, aligning with the treat-to-target approach endorsed by EULAR recommendations.10 19 Early aggressive treatment to achieve remission or low disease activity may be particularly crucial for preserving physical function in older patients who may have less physiological reserve to compensate for organ damage. Education level emerged as a significant determinant of both PCS and MCS scores, with lower education associated with poorer physical health. This complex relationship between education and HRQoL in SLE may reflect underlying socioeconomic factors, healthcare access disparities or differences in illness perceptions that influence health outcomes.20 These findings suggest that socioeconomic factors should be considered when developing strategies to improve HRQoL in SLE patients. The positive association between haemoglobin levels and PCS highlights the potential impact of anaemia on physical well-being in patients with SLE. Anaemia, a frequent manifestation of SLE, is known to contribute to fatigue and impaired PF.21 Nonetheless, haemoglobin levels may also serve as an indirect marker of broader systemic conditions beyond anaemia. In particular, malnutrition and frailty, both not uncommon in patients with chronic autoimmune diseases, could contribute to reduced haemoglobin levels and, in turn, adversely affect HRQoL.22 Indeed, a recent cross-sectional study reported that nearly half of SLE patients exhibited malnutrition, with lower haemoglobin being an independent predictor, while chronic inflammation, gastrointestinal involvement and increased metabolic demands may further exacerbate nutritional deficits.22 Thus, the observed association should be interpreted with caution, as it may not exclusively represent SLE-related haematologic dysfunction but rather an interplay of nutritional, metabolic and systemic factors influencing physical health. Given the cross-sectional nature of our study, we cannot determine whether low haemoglobin primarily reflects SLE-related haematologic abnormalities, nutritional status or both. Future longitudinal studies incorporating nutritional assessments and markers of frailty are warranted to disentangle these complex relationships. Our observation of no significant independent association between age group and MCS scores is consistent with previous SLE literature, including the Georgians Organized Against Lupus study and Italian cohorts, which similarly found no age-related MH patterns.23 This contrasts with other rheumatic diseases where older patients showed improved MH scores.24 The absence of age-related MH decline in SLE suggests that MH is determined more by disease-specific factors, gender, education and treatment than by age itself, contrasting with the direct effect of age on PF and highlighting the complex psychosocial adaptation to chronic disease across the lifespan.23 This complexity is further evidenced by medication use patterns that varied across age groups, with prednisolone negatively affecting physical health and cyclophosphamide affecting MH, reflecting the dual burden of disease activity requiring intensive treatment and medication side effects.25 These findings emphasise the importance of steroid-sparing strategies and targeted therapy approaches to minimise treatment-related adverse effects while maintaining disease control across all age groups. The analysis of specific organ damage manifestations on HRQoL domains provides novel insights into how different types of damage affect patient well-being. With 1149 SLE patients, our study represents one of the largest investigations of this relationship to date, substantially exceeding previous studies such as Gergianaki et al26 and Elefante et al.27 This larger sample size enabled us to detect more subtle but clinically meaningful relationships between specific damage manifestations and HRQoL domains with greater statistical confidence. Additionally, this study is the first to comprehensively analyse how individual organ damage types (avascular necrosis, reduced GFR, malignancy, osteoporosis, cataracts and diabetes mellitus) differentially impact specific SF-36 domains—a domain-to-domain analysis approach not previously reported in SLE literature. These distinct patterns reveal important insights into how different damage types affect specific quality of life domains. The severe impact of avascular necrosis on physical domains, particularly BP and PF, likely reflects the significant mobility limitations and pain associated with this condition, underscoring the importance of early detection and management. The broader multidomain impairment observed in patients with malignancy and reduced renal function suggests these conditions affect both physical and psychological well-being across multiple SF-36 domains, highlighting the critical importance of vigilant screening and comprehensive management approaches. These detailed domain-specific insights, uniquely possible with our large cohort, provide clinicians with more precise guidance for targeted interventions addressing the most severely affected aspects of quality of life in patients with specific organ damage manifestations, with important implications for comprehensive clinical management and patient care strategies. Interestingly, while PF declined with age, VT scores were higher in the older age group. This paradoxical finding might reflect psychological adaptation to chronic illness over time, with older patients developing more effective energy conservation strategies or adjusting expectations regarding physical capabilities.24 28 It could also relate to the different disease manifestations across age groups, with younger patients experiencing more systemic inflammation that contributes to fatigue despite better PF. Recent research has provided valuable insights into resilience mechanisms specific to autoimmune rheumatic diseases, which offer important perspectives on psychological adaptation processes over time. Studies examining resilience in women with autoimmune rheumatic diseases have identified that psychological adaptation in these conditions involves complex, disease-specific coping mechanisms that may explain why traditional age-related patterns of improved MH outcomes are not consistently observed.29 30 These findings suggest that the unpredictable nature of SLE may require continuous psychological readjustment regardless of patient age, potentially explaining our observation of no significant age-related differences in MCS. Longer disease duration in older adults might reveal different relationship patterns, as extended exposure to chronic illness can lead to cumulative disease effects and evolving psychological adaptation strategies not fully captured in our sample. Our study also did not include measures of social support, coping strategies or resilience, which may mediate relationships between clinical factors and HRQoL, particularly in the MH domain. Finally, the use of categorical variables, while clinically relevant, may have resulted in some loss of statistical information. Future longitudinal studies incorporating these psychosocial factors and examining older adults with extended disease duration would provide more comprehensive understanding of HRQoL trajectories in SLE patients across different life stages and disease courses. This study has several strengths, including its large sample size, comprehensive assessment of both physical and MH dimensions and detailed analysis of multiple potential determinants of HRQoL. The inclusion of patients across a wide age spectrum allowed for meaningful comparisons between different life stages. Additionally, the analysis of specific organ damage manifestations provides clinically relevant information for targeted interventions. A potential limitation of our study is survival bias, given the long disease duration at baseline. Patients with severe disease or poor outcomes may have been underrepresented due to mortality or loss to follow-up, resulting in a cohort skewed toward milder phenotypes and better treatment responses. This bias may limit the generalisability of our findings, and future inception cohort studies are needed to capture the full spectrum of disease severity. Clinical implications The findings about the younger patients (<20 years) suggest that interventions should focus on educational support and disease activity management to minimise future damage accrual. In the middle-age group (20–50 years), balancing treatment efficacy with minimising side effects is crucial, particularly regarding steroid exposure. For older patients (≥50 years), targeted interventions to maintain physical function, manage pain from conditions like avascular necrosis and address comorbidities should be prioritised. Across all age groups, regular assessment of HRQoL using validated tools like SF-36 can help identify specific domains requiring intervention, allowing for personalised management approaches. Age-tailored management approaches should address the specific needs of different age groups, with damage prevention emphasised as a universal goal to optimise HRQoL. Specific organ damage manifestations create distinct patterns of HRQoL impairment, suggesting the need for targeted interventions based on the specific type of damage. Psychosocial support may be particularly important for patients with certain types of damage or treatments associated with poorer MH outcomes. Future research should focus on developing and testing age-specific interventions to improve HRQoL in SLE patients, with particular attention to preventing organ damage and addressing the specific physical limitations experienced by older patients. Conclusion This study demonstrates significant age-related differences in the physical dimensions of HRQoL among SLE patients, with older patients experiencing poorer PF despite similar MH outcomes. Organ damage, educational level and specific treatments emerged as key determinants of both physical and MH components across all age groups. These findings highlight the importance of personalised, age-specific approaches to SLE management focused on damage prevention to optimise patients’ HRQoL. Supplementary material Acknowledgements We would like to thank Taichung Veterans General Hospital for their assistance in this study. Footnotes Funding: The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors. Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: This study involves human participants and the study protocol was approved by the institutional ethics committee of Taichung Veterans General Hospital (IRB No. CE17061B), and all participants provided written informed consent. Participants gave informed consent to participate in the study before taking part. Patient and public involvement: Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research. Data availability statement Data are available upon reasonable request. References Associated Data Supplementary Materials Data Availability Statement Data are available upon reasonable request.